- Home
- AXL vs ANAB Comparison
AXL vs ANAB Comparison
Compare AXL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- ANAB
- Stock Information
- Founded
- AXL 1994
- ANAB 2005
- Country
- AXL United States
- ANAB United States
- Employees
- AXL N/A
- ANAB N/A
- Industry
- AXL Auto Parts:O.E.M.
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- ANAB Health Care
- Exchange
- AXL Nasdaq
- ANAB Nasdaq
- Market Cap
- AXL 715.5M
- ANAB 659.6M
- IPO Year
- AXL 1999
- ANAB 2017
- Fundamental
- Price
- AXL $6.51
- ANAB $35.04
- Analyst Decision
- AXL Buy
- ANAB Buy
- Analyst Count
- AXL 7
- ANAB 11
- Target Price
- AXL $6.93
- ANAB $57.00
- AVG Volume (30 Days)
- AXL 3.3M
- ANAB 581.9K
- Earning Date
- AXL 11-07-2025
- ANAB 10-31-2025
- Dividend Yield
- AXL N/A
- ANAB N/A
- EPS Growth
- AXL 3967.82
- ANAB N/A
- EPS
- AXL 0.35
- ANAB N/A
- Revenue
- AXL $5,833,200,000.00
- ANAB $123,164,000.00
- Revenue This Year
- AXL N/A
- ANAB $11.62
- Revenue Next Year
- AXL N/A
- ANAB $15.31
- P/E Ratio
- AXL $18.69
- ANAB N/A
- Revenue Growth
- AXL N/A
- ANAB 304.17
- 52 Week Low
- AXL $3.00
- ANAB $12.21
- 52 Week High
- AXL $7.03
- ANAB $35.77
- Technical
- Relative Strength Index (RSI)
- AXL 64.96
- ANAB 70.65
- Support Level
- AXL $5.37
- ANAB $33.01
- Resistance Level
- AXL $5.77
- ANAB $35.58
- Average True Range (ATR)
- AXL 0.26
- ANAB 1.64
- MACD
- AXL 0.07
- ANAB -0.08
- Stochastic Oscillator
- AXL 91.60
- ANAB 88.23
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).